This invaluable resource presents a wealth of deal terms and royalty rates that will provide those in the middle of technology license negotiations with real-world guidance
$1,850.00
View table of contents | View sample pages
Royalty Rates for Pharmaceuticals & Biotechnology features more real-deal royalty rates, license fees, and milestone payment benchmarks than any other publication.
This invaluable resource presents a wealth of deal terms and royalty rates that will provide those in the middle of technology license negotiations with real-world guidance. With over 550 transactions that include the technology licensed, royalty rates, upfront license fees, and milestone payments, this edition emphasizes the reporting of royalty rates and other financial compensation associated with each license agreement.
The data covers a wide variety of technologies. Just some of the technology categories represented include: Alzheimer’s, asthma, cardiovascular, cancer, contraception, diabetes, dermatology, drug delivery, hepatitis, pain management, personal care, sleep therapy, and vaccines.
You’ll find information on the parties involved in the transactions along with a description of the technology exchanged and all financial details that could be discovered.
Royalty Rates for Pharmaceuticals & Biotechnology, 9th Edition is provided as a PDF download. Once you order, you get immediate access to this invaluable data.
IPRA is a consulting and publishing organization headed by founder Russell L. Parr, CFA, ASA, who has decades of consulting experience involving the valuation and pricing of patents, trademarks, copyrights and other intangible assets.
